Therapeutic effects of Shenfu Injection on post-cardiac arrest syndrome.
10.1007/s11655-013-1566-8
- Author:
Zhi-jun GUO
1
;
Chun-sheng LI
Author Information
1. Emergency Department of Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Cardiotonic Agents;
pharmacology;
therapeutic use;
Drugs, Chinese Herbal;
administration & dosage;
therapeutic use;
Heart Arrest;
drug therapy;
physiopathology;
Humans;
Injections;
Neuroprotective Agents;
pharmacology;
therapeutic use;
Syndrome
- From:
Chinese journal of integrative medicine
2013;19(9):716-720
- CountryChina
- Language:English
-
Abstract:
Survival rates after cardiac arrest have not changed substantially over the past 5 decades. Postcardiac arrest (CA) syndrome (PCAS) is the primary reason for the high mortality rate after successful restoration of spontaneous circulation (ROSC). Intravenous administration of Shenfu Injection (, SFI) may attenuate post-CA myocardial dysfunction and cerebral injury, inhibit systemic ischemia/reperfusion responses, and treat underlying diseases. In this article, we reviewed the therapeutic effects of SFI in PCAS. SFI might be useful in the treatment of PCAS, incorporating the multi-link and multi-target advantages of Chinese medicine into PCAS management. Further experimental and clinical research to verify the therapeutic effects of SFI in PCAS is required.
